Literature DB >> 18923714

ESBL genotypes in fluoroquinolone-resistant and fluoroquinolone-susceptible ESBL-producing Escherichia coli urinary isolates in Manitoba.

Philippe Rs Lagacé-Wiens1, Kim A Nichol, Lindsay E Nicolle, Mel R Decorby, Melissa McCracken, Michelle J Alfa, Michael R Mulvey, George G Zhanel.   

Abstract

OBJECTIVE: Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are increasingly common in nosocomial and community settings. Furthermore, fluoroquinolone (FQ) and even multidrug resistance (MDR) appear to be associated with certain ESBL genotypes. The purpose of the present study was to determine which ESBL genotypes are associated with FQ and MDR in E coli urinary isolates in Manitoba.
METHODS: The authors determined the antimicrobial susceptibility, genetic similarity and ESBL genotype of 27 FQ-resistant and seven FQ-susceptible, ESBL-producing urinary isolates submitted to the clinical microbiology laboratories of two teaching hospitals between October 2000 and April 2005. Susceptibilities to beta-lactams, FQs, trimethoprim-sulfamethoxazole (SXT), doxycycline (DOX), gentamicin (GM) and tigecycline were determined by microbroth dilution; pulsed-field gel electrophoresis (PFGE) was used to determine genetic relatedness, and ESBL genotype was determined by polymerase chain reaction and sequencing.
RESULTS: Of 34 ESBL-producing organisms, 27 (79.4%) were found to be ciprofloxacin (CIP) resistant, 27 (79.4%) were SXT resistant, eight (23.5%) were GM resistant and 29 (85.3%) were DOX resistant. Twenty-three (67.6%) had MDR, with concomitant resistance to CIP and SXT; 16 had concomitant resistance to CIP, SXT and DOX; and seven (20.6%) had MDR, with concomitant resistance to CIP, SXT, DOX and GM. All isolates were susceptible to tigecycline. Of 27 FQ-resistant ESBL-producing organisms, seven (25.9%) were genotype CTX-M-14, 19 (70.4%) were genotype CTX-M-15 and one (3.7%) was genotype CTX-M-24. Among the seven FQ-susceptible strains, three (42.8%) expressed SHV-type enzymes, three (42.8%) expressed TEM-type enzymes and one (14.3%) expressed CTX-M-9. CTX-M-15 was the most common MDR-associated genotype. Of a total of 19 strains, 18 (94.7%) were resistant to FQs and SXT; 15 (78.9%) were resistant to FQs, SXT and DOX; and five (26.3%) were resistant to FQs, SXT, DOX and GM. PFGE analysis revealed genetic similarity within CTX-M-15-producing isolates only.
CONCLUSION: CTX-M-15 in E coli is strongly associated with an MDR phenotype compared with other genotypes. CTX-M-14 is associated with FQ resistance only. PFGE suggests clonality of CTX-M-15-producing isolates within and among hospitals.

Entities:  

Keywords:  CTX-M-15; ESBL; Escherichia coli; Fluoroquinolone-resistant; Molecular epidemiology; Multidrug-resistant

Year:  2007        PMID: 18923714      PMCID: PMC2533543          DOI: 10.1155/2007/848194

Source DB:  PubMed          Journal:  Can J Infect Dis Med Microbiol        ISSN: 1712-9532            Impact factor:   2.471


  24 in total

1.  Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.

Authors:  Aránzazu Valverde; Teresa M Coque; M Paz Sánchez-Moreno; Azucena Rollán; Fernando Baquero; Rafael Cantón
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

2.  Properties of plasmids responsible for production of extended-spectrum beta-lactamases.

Authors:  G A Jacoby; L Sutton
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

Review 3.  Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon.

Authors:  M N Alekshun; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

4.  Quinolone resistance from a transferable plasmid.

Authors:  L Martínez-Martínez; A Pascual; G A Jacoby
Journal:  Lancet       Date:  1998-03-14       Impact factor: 79.321

5.  Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada.

Authors:  David A Boyd; Shaun Tyler; Sara Christianson; Allison McGeer; Matthew P Muller; Barbara M Willey; Elizabeth Bryce; Michael Gardam; Patrice Nordmann; Michael R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 6.  Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.

Authors:  Aamer Ali Shah; Fariha Hasan; Safia Ahmed; Abdul Hameed
Journal:  Res Microbiol       Date:  2004 Jul-Aug       Impact factor: 3.992

7.  Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Authors:  David L Paterson; Wen-Chien Ko; Anne Von Gottberg; Sunita Mohapatra; Jose Maria Casellas; Herman Goossens; Lutfiye Mulazimoglu; Gordon Trenholme; Keith P Klugman; Robert A Bonomo; Louis B Rice; Marilyn M Wagener; Joseph G McCormack; Victor L Yu
Journal:  Clin Infect Dis       Date:  2004-06-08       Impact factor: 9.079

8.  Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes.

Authors:  Johann D D Pitout; Nancy D Hanson; Deirdre L Church; Kevin B Laupland
Journal:  Clin Infect Dis       Date:  2004-05-25       Impact factor: 9.079

9.  RamA is an alternate activator of the multidrug resistance cascade in Enterobacter aerogenes.

Authors:  Renaud Chollet; Jacqueline Chevalier; Claude Bollet; Jean-Marie Pages; Anne Davin-Regli
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

10.  Laboratory investigation of a multistate food-borne outbreak of Escherichia coli O157:H7 by using pulsed-field gel electrophoresis and phage typing.

Authors:  T J Barrett; H Lior; J H Green; R Khakhria; J G Wells; B P Bell; K D Greene; J Lewis; P M Griffin
Journal:  J Clin Microbiol       Date:  1994-12       Impact factor: 5.948

View more
  7 in total

Review 1.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

2.  Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Authors:  A Dalhoff; S Schubert; A Vente
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Genotypic antimicrobial resistance characterization of E. coli from dairy calves at high risk of respiratory disease administered enrofloxacin or tulathromycin.

Authors:  R V Pereira; C Foditsch; J D Siler; S C Dulièpre; C Altier; A Garzon; L D Warnick
Journal:  Sci Rep       Date:  2020-11-09       Impact factor: 4.379

4.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14

5.  Fluoroquinolone resistance among gram-negative urinary tract pathogens: global smart program results, 2009-2010.

Authors:  Sam Bouchillon; Daryl J Hoban; Robert Badal; Stephen Hawser
Journal:  Open Microbiol J       Date:  2012-09-07

6.  Antimicrobial susceptibility pattern of extended-spectrum β-lactamase-producing bacteria causing nosocomial urinary tract infections in an Iranian referral teaching hospital.

Authors:  Rasool Soltani; Mohsen Ehsanpoor; Farzin Khorvash; Dariush Shokri
Journal:  J Res Pharm Pract       Date:  2014-01

Review 7.  Genetic diversity and risk factors for the transmission of antimicrobial resistance across human, animals and environmental compartments in East Africa: a review.

Authors:  Bugwesa Z Katale; Gerald Misinzo; Stephen E Mshana; Harriet Chiyangi; Susana Campino; Taane G Clark; Liam Good; Mark M Rweyemamu; Mecky I Matee
Journal:  Antimicrob Resist Infect Control       Date:  2020-08-06       Impact factor: 4.887

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.